Abstract 2631: LPD002, a novel anti-PD-1/IL-2 fusion protein, demonstrates potent antitumor activity in preclinical studies.

Preclinical studies demonstrate LPD002 enhances anti-tumor efficacy in PD-1 models, suggesting a promising therapeutic approach.